Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening
Dados Bibliográficos
| ID | 9102574 |
|---|---|
| Autores | S Lucas Goede (0000-0003-4319-4397, Erasmus MC, autor correspondente), Karen M Kuntz (0000-0001-6335-7590, University of Minnesota), Marjolein Van Ballegooijen (Erasmus MC, autor correspondente), Amy B Knudsen (0000-0003-1872-996X, Massachusetts General Hospital), Iris Lansdorp-Vogelaar, Iris Lansdorp‐Vogelaar (0000-0002-9438-2753, Erasmus MC, autor correspondente), Florence K Tangka, Florence K L Tangka (0000-0002-0120-6401), David H Howard (0000-0002-4465-0414, Emory University), Joseph Chin (Centers for Medicare and Medicaid Services), Ann G Zauber (0000-0002-1764-5994, Memorial Sloan Kettering Cancer Center), Laura C Seeff |
| Ano | 2015 |
| Volume | 53 |
| Fascículo | 7 |
| Páginas | 630-638 |
| Data de publicação | 2015-07-01 |
| Peer Reviewed | Sim |
| Open Access | Não |
| Tipo | ARTICLE |
| Periódico | Medical Care (JOURNAL) |
| Identificadores do periódico | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Editora | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/mlr.0000000000000380 |
| PMID | 26067885 |
| PMCID | PMC4467468 |
| OpenAlex | W2207790881 |
| Idioma | EN |
| Citações recebidas | 1 |
| Referências citadas | 35 |
BACKGROUND: Many individuals have not received recommended colorectal cancer (CRC) screening before they become Medicare eligible at the age of 65. We aimed to estimate the long-term implications of increased CRC screening in the pre-Medicare population (50-64 y) on costs in the pre-Medicare and Medicare populations (65+ y). METHODS: We used 2 independently developed microsimulation models [Microsimulation Screening Analysis Colon (MISCAN) and Simulation Model of CRC (SimCRC)] to project CRC screening and treatment costs under 2 scenarios, starting in 2010: "current trends" (60% of the population up-to-date with screening recommendations) and "enhanced participation" (70% up-to-date). The population was scaled to the projected US population for each year between 2010 and 2060. Costs per year were derived by age group (50-64 and 65+ y). RESULTS: By 2060, the discounted cumulative total costs in the pre-Medicare population were $35.7 and $28.1 billion higher with enhanced screening participation, than in the current trends scenario ($252.1 billion with MISCAN and $239.5 billion with SimCRC, respectively). Because of CRC treatment savings with enhanced participation, cumulative costs in the Medicare population were $18.3 and $32.7 billion lower (current trends: $423.5 billion with MISCAN and $372.8 billion with SimCRC). Over the 50-year time horizon an estimated 60% (MISCAN) and 89% (SimCRC) of the increased screening costs could be offset by savings in Medicare CRC treatment costs. CONCLUSION: Increased CRC screening participation in the pre-Medicare population could reduce CRC incidence and mortality, whereas the additional screening costs can be largely offset by long-term Medicare treatment savings
Cancer · Cohort · Colonoscopy · Colorectal cancer · Colorectal cancer screening · Cost–benefit analysis · Cumulative incidence · Environmental health · Microsimulation · Population · Colorectal Cancer Screening and Detection · Colorectal Cancer Surgical Treatments · Demography · Global Cancer Incidence and Screening · Internal Medicine · Medicine · Gerontology
| Obras citantes distintas | 1 |
|---|---|
| Citações por ano | 1 |
| Intervalo de citações | 2025 - 2025 (1) |
| Velocidade de citação | recent |
| Altamente citado | Não |